S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:MBRX - Moleculin Biotech Stock Price, Forecast & News

$1.02
-0.02 (-1.92 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$1.01
Now: $1.02
$1.04
50-Day Range
$1.01
MA: $1.06
$1.13
52-Week Range
$0.78
Now: $1.02
$3.15
Volume159,220 shs
Average Volume1.18 million shs
Market Capitalization$46.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBRX
CUSIPN/A
Phone713-300-5160

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.53 per share

Profitability

Net Income$-11,880,000.00

Miscellaneous

Employees9
Market Cap$46.10 million
Next Earnings Date2/20/2020 (Estimated)
OptionableNot Optionable

Receive MBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.


Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech Inc (NASDAQ:MBRX) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.00. View Moleculin Biotech's Earnings History.

When is Moleculin Biotech's next earnings date?

Moleculin Biotech is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Moleculin Biotech.

What price target have analysts set for MBRX?

3 brokers have issued 12-month price objectives for Moleculin Biotech's shares. Their forecasts range from $2.00 to $8.00. On average, they anticipate Moleculin Biotech's share price to reach $4.33 in the next year. This suggests a possible upside of 324.8% from the stock's current price. View Analyst Price Targets for Moleculin Biotech.

What is the consensus analysts' recommendation for Moleculin Biotech?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Moleculin Biotech.

What are Wall Street analysts saying about Moleculin Biotech stock?

Here are some recent quotes from research analysts about Moleculin Biotech stock:
  • 1. According to Zacks Investment Research, "Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. " (12/4/2019)
  • 2. Maxim Group analysts commented, "Moleculin reported YE18 with a net loss of ($11.9M) and ended the period with ~$7M in cash, runway into 3Q19. The company also has $18M remaining on an equity line. Management continued to execute in 2018 and position its two lead programs (Annamycin and the STAT3 candidates) to reach data points in 2019, which should if positive unlock value for MBRX shareholders. Important in our view is to focus on why these assets are differentiated in the oncology space and how that could translate into a higher probability of success in the clinic. We review in more detail below." (2/26/2019)

Has Moleculin Biotech been receiving favorable news coverage?

News coverage about MBRX stock has trended positive on Tuesday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Moleculin Biotech earned a news sentiment score of 2.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Moleculin Biotech.

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a decrease in short interest in October. As of October 31st, there was short interest totalling 1,930,000 shares, a decrease of 10.6% from the September 30th total of 2,160,000 shares. Based on an average trading volume of 175,000 shares, the short-interest ratio is currently 11.0 days. Approximately 5.0% of the shares of the stock are short sold. View Moleculin Biotech's Current Options Chain.

Who are some of Moleculin Biotech's key competitors?

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Rite Aid (RAD), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO), Exelixis (EXEL), AcelRx Pharmaceuticals (ACRX), SCYNEXIS (SCYX), Novavax (NVAX), vTv Therapeutics (VTVT), Palatin Technologies (PTN) and BioTelemetry (BEAT).

Who are Moleculin Biotech's key executives?

Moleculin Biotech's management team includes the folowing people:
  • Mr. Walter V. Klemp, Founder, Chairman, Pres & CEO (Age 59)
  • Mr. Jonathan P. Foster, CFO & Exec. VP (Age 55)
  • Dr. Donald H. Picker, Chief Scientific Officer (Age 73)
  • Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard, Chief Medical Officer (Age 67)

Who are Moleculin Biotech's major shareholders?

Moleculin Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.47%). View Institutional Ownership Trends for Moleculin Biotech.

Which major investors are buying Moleculin Biotech stock?

MBRX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Moleculin Biotech.

How do I buy shares of Moleculin Biotech?

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.02.

How big of a company is Moleculin Biotech?

Moleculin Biotech has a market capitalization of $46.10 million. The company earns $-11,880,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Moleculin Biotech employs 9 workers across the globe.View Additional Information About Moleculin Biotech.

What is Moleculin Biotech's official website?

The official website for Moleculin Biotech is http://www.moleculin.com/.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at 713-300-5160.


MarketBeat Community Rating for Moleculin Biotech (NASDAQ MBRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe MBRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel